Back to Results
First PageMeta Content
Antibiotics / Université Lille Nord de France / Pharmaceuticals policy / Tropical diseases / Institut Pasteur de Lille / Pasteur Institute / Neglected diseases / Medical research / GlaxoSmithKline / Health / Medicine / Tuberculosis


SWITCHING OFF BACTERIAL RESISTANCE BioVersys with the support of the University of Lille and GlaxoSmithKline to develop preclinical candidates in tuberculosis Basel (Switzerland), Lille (France), May[removed] – BioVers
Add to Reading List

Document Date: 2014-05-27 00:44:29

Open Document

File Size: 263,23 KB

Share Result on Facebook

City

Zurich / Lille / /

Company

GlaxoSmithKline / BioVersys AG / The Wellcome Trust / Eisei GmbH / /

Country

Switzerland / France / /

/

Event

Business Partnership / /

Facility

University of Lille / /

IndustryTerm

biopharmaceutical / drug technologies / /

MedicalCondition

TB / disease / neglected disease / Mycobacterium tuberculosis / active TB / threat Tuberculosis / diseases / bacterial infectious disease / tuberculosis / /

MedicalTreatment

rejuvenation / antibiotics / /

Organization

Centre National / World Health Organization / University of Lille / Institut Pasteur de Lille / Institut National / Faculty of Pharmacy / /

Person

Marc Gitzinger / Richard Seabrook / Professors Nicolas Willand / Bénoit Deprez / Benoît Deprez / Daniel Piller / Alain Baulard / /

/

Position

CEO / Director of Research / Professor of Chemistry / Head of Business Development / /

Technology

drug discovery / TRIC technology / drug technologies / /

URL

www.irfcom.ch / www.wellcome.ac.uk / www.bioversys.com / /

SocialTag